Results 131 to 140 of about 6,125,000 (281)

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

Estimation of All-Sky Gridded Diurnal Near-Surface Air Temperatures at Regional Scale From FY-4B Measurements

open access: yesIEEE Journal of Selected Topics in Applied Earth Observations and Remote Sensing
The near-surface air temperature (${{T}_{air}}$) is a principal variable describing energy exchange and water circulation between the land surface and the atmospheric environment. The estimation of ${{T}_{air}}$ by satellite land surface temperature (LST)
Ronghan Xu   +7 more
doaj   +1 more source

Adaptation and Validation of the Brazilian Version of the Utrecht Work Engagement Scale [PDF]

open access: diamond, 2015
Ana Cláudia Souza Vazquez   +4 more
openalex   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

open access: yesMolecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski   +19 more
wiley   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Accurate Satellite Operation Predictions Using Attention-BiLSTM Model with Telemetry Correlation

open access: yesAerospace
In satellite health management, anomalies are mostly resolved after an event and are rarely predicted in advance. Thus, trend prediction is critical for avoiding satellite faults, which may affect the accuracy and quality of satellite data and even ...
Yi Peng, Shuze Jia, Lizi Xie, Jian Shang
doaj   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias   +12 more
wiley   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Prediction for Cycloplegic Refractive Error in Chinese School Students: Model Development and Validation

open access: gold, 2022
Jianyong Wang   +15 more
openalex   +1 more source

Home - About - Disclaimer - Privacy